Autonomix Medical Inc (NASDAQ:AMIX) jumped nearly 14% in premarket trading on Friday after the company released encouraging clinical results showing sustained pain relief in patients with pancreatic cancer, including those with advanced disease.
The medical device developer unveiled new subgroup findings from its proof-of-concept study at the 2026 ASCO Gastrointestinal Cancers Symposium. The analysis highlighted fast-acting, durable and clinically meaningful reductions in pain linked to pancreatic cancer, with benefits observed across all stages of the disease.
Study data showed that 93.75% of patients who responded to treatment shifted from severe pain to mild or moderate pain within seven days of undergoing the procedure. At four to six weeks after treatment, around two-thirds of responders continued to report pain at mild levels or complete relief. By the three-month mark, none of the responding patients indicated severe pain.
Importantly, the results were consistent across disease stages, including patients with Stage 4 pancreatic cancer, a group that typically has limited therapeutic options. Several patients with terminal disease experienced a marked improvement from severe pain to mild or moderate discomfort, with some reporting near-total pain relief.
“Seeing patients move from severe pain to mild or near-elimination levels of pain, even in the most advanced stages of pancreatic cancer, is extraordinarily encouraging,” said Brad Hauser, President and CEO of Autonomix Medical. “These findings reinforce our belief that a targeted, nerve-based approach has the potential to provide meaningful relief when traditional pharmacologic and interventional options fall short.”
Autonomix Medical is developing precision, nerve-focused therapies built around its transvascular radiofrequency denervation platform. The company’s technology is designed to address pancreatic cancer–related pain, which remains one of the most severe and difficult challenges in oncology care.